Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + PD-1 Inhibitor in Metastatic Pancreatic Cancer
NCT05218629Phase 2Unknown
- Sponsor
- Affiliated Qingdao Central Hospital of Qingdao University
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in pancreatic adenocarcinoma (PDAC), sponsored by Affiliated Qingdao Central Hospital of Qingdao University. Status: unknown.
02
Drugs
anlotinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05218629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05218629.